Sign up for the
Join the Women's Health Advocates community that is uniting people to educate government decision-makers on policies and funding needed to advance the health of women.
JP MORGAN AND CONFERENCES ON WOMEN'S HEALTH
On January 13, 2026 Women's Health Advocates teamed up with AOA Dx, Goodwin Procter, HSBC Bank and Cure to host New Data on Big Returns for Investors in Women’s Health. The event is full and we are not taking any more registrants, but please stay tuned for future events.
The Founding Leaders of Women's Health Advocates have served as speakers for several JP Morgan Healthcare Conference related events over the years. The growth in interest, programming and collaboration in women's health innovation in recent years is promising. However, government policy and increased funding that incentivizes more investment is necessary to accelerate bringing medical innovations to patients.
If you are planning conferences addressing women's health, please let us know. We would be happy to participate or support your efforts. Collaboration is key to closing gaps and advancing the health of women!
Policy Work
HEALTH AND HUMAN SERVICES REMOVES BLACK BOX LABEL TO ENABLE HRT ACCESS FOR MENOPAUSE—In December 2025, Women's Health Advocates attended the announcement by FDA to remove the across-the-board black box label for hormone replacement therapy or hormone therapy as utilization has fallen to 5% despite data on the benefits of HRT for millions of women. Consultation with physicians is key for women to get the care that is best for them, and this action enables these conversations based on evidence.
— — — — — — — — — — — — — — — — — — — — — — — — — — — — —
NEW WHITE HOUSE INITIATIVE ON WOMEN'S HEALTH RESEARCH—Launched in November 2023, the initiative led to increased sex-based data collection, analysis and sharing and new interagency collaborations to better understand and treat the needs of patients with regard to diseases and conditions that solely, disproportionately and/or differently impact the health of women from head to toe over the lifespan. We participated in the White House events and the ARPA-H Sprint for Women's Health launch and worked to provide valuable insights based on the expertise and wisdom of the many founders, executives, VCs, researchers, clinicians, patients and nonprofits we work with.
— — — — — — — — — — — — — — — — — — — — — — — — — — — — —
CMS COVERAGE FOLLOWING FDA BREAKTHROUGH DESIGNATION— We wrote and submitted letters and led grassroots campaign to advocate for closing the gap between FDA approval and CMS coverage. Organized webinars and guidance on TCET and submitting comments to CMS. We continue to educate Congress on changes needed to ensure medical innovations approved by FDA are made available within CMS, and that the reimbursement rates are not lower for female-specific surgeries.
ACCURACY AND INCLUSION IN RESEARCH—
- NIH – Advocated for new requirements for NIH regarding recruitment and engagement in studies to ensure diversity in clinical trials in legislation
- OFFICE OF RESEARCH ON WOMEN’S HEALTH – Collaborated and supported efforts, such as the Women's Health Consensus Conference and the new Autoimmune Office within the Office of Research on Women's Health (ORWH), and advocated for increased NIH research funding dedicated to women’s health
- FDA – Strengthened oversight of population studies to include data on sex differences in drug response, transparency in biological sex differences and assessment of participation barriers, such as travel costs, timing for trial appointments, appointment locations, and the use of online clinical care and other factors that often exclude diverse populations in legislation
ADVERSE DRUG EVENTS – Wrote and submitted regulatory comments to push for adverse drug events and patient safety concerns being reported by sex and ethnicity to ensure data is captured to inform care as ADRs are twice as common in women
AUTOIMMUNE DISEASES – Led letter writing campaign to Congress to increase funding for research, which resulted in a new $10 million initiative
MENOPAUSE & AGING – Wrote letter to Congress on the need for no co-pays for menopause related doctor's visits and organized meeting with the Deputy Assistant Secretary for Women's Health to address aging women’s health, including menopause
OVARIAN CANCER – Helped draft legislation to address the gap in testing of pelvic masses that impacts 1 in 5 women and is vital to early identification of ovarian cancer, and worked with CMS on coverage for new technologies
WOMEN’S HEALTH EQUITY – Crafted policy proposal to close gaps in women’s health research, medical training, diagnostics and clinical care, and organized Congressional and Harvard Business School presentations on women's health
Join the Women's Health Advocates Steering Committee
Join the Steering Committee to shape the direction of the Women’s Health Advocates initiative with direct access to the professional lobbying team and network of national leaders and invitations to events and meetings with Congress and agencies.
TAKE ACTION
Sign up to receive information on policies, government funding, and events addressing women’s health issues.